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Invasion of erythrocytes by malaria parasites is medi-
ated by specific molecular interactions. Plasmodium
vivax is completely dependent on interaction with the
Duffy blood group antigen to invade human erythro-
cytes. The P. vivax Duffy-binding protein, which binds
the Duffy antigen during invasion, belongs to a family of
erythrocyte-binding proteins that also includes Plasmo-
dium falciparum sialic acid binding protein and Plas-
modium knowlesi Duffy binding protein. The receptor
binding domains of these proteins lie in a conserved,
N-terminal, cysteine-rich region, region II, found in each
of these proteins. Here, we have expressed P. vivax re-
gion II (PvRII), the P. vivax Duffy binding domain, in
Escherichia coli. Recombinant PvRII is incorrectly
folded and accumulates in inclusion bodies. We have
developed methods to refold and purify recombinant
PvRII in its functional conformation. Biochemical, bio-
physical, and functional characterization confirms that
recombinant PvRII is pure, homogeneous, and function-
ally active in that it binds Duffy-positive human eryth-
rocytes with specificity. Refolded PvRII is highly immu-
nogenic and elicits high titer antibodies that can inhibit
binding of P. vivax Duffy-binding protein to erythro-
cytes, providing support for its development as a vac-
cine candidate for P. vivax malaria. Development of
methods to produce functionally active recombinant
PvRII is an important step for structural studies as well
as vaccine development.
The invasion of erythrocytes by malaria parasites is medi-
ated by specific molecular interactions between host receptors
and parasite ligands (1). Plasmodium vivax and the related
simian malaria parasite Plasmodium knowlesi require interac-
tion with the Duffy blood group antigen to invade human
erythrocytes (2, 3). P. knowlesi can also invade rhesus eryth-
rocytes using alternative Duffy-independent receptors (4). P.
falciparum commonly uses sialic acid residues of glycophorin A
as invasion receptors (5–9). Like P. knowlesi, P. falciparum
also invades erythrocytes by multiple pathways and is not
completely dependent on sialic acid residues of glycophorin A
(8, 10, 12, 13).
Parasite ligands that bind host receptors to mediate eryth-
rocyte invasion include P. vivax and P. knowlesi Duffy-binding
proteins, P. knowlesi b and g proteins, which bind Duffy-inde-
pendent receptors on rhesus erythrocytes, and P. falciparum
sialic acid-binding protein (also known as EBA-175), which
binds sialic acid residues on glycophorin A (4, 14–18). These
parasite ligands share similar features and belong to a family
of erythrocyte-binding proteins (19). The extracellular domain
of each erythrocyte-binding protein contains two conserved
cysteine-rich regions, regions II and VI, at the amino and
carboxyl ends, respectively. P. falciparum EBA-175 contains a
tandem duplication (F1 and F2) of the N-terminal, conserved,
cysteine-rich region. The functional receptor binding domain of
each erythrocyte-binding protein lies in region II (20, 21). In
the case of EBA-175, region F2 was found to have receptor
binding activity (21). P. vivax region II (PvRII)1 specifically
binds the human Duffy antigen, and P. falciparum region F2
specifically binds sialic acid residues of glycophorin A. Region
II of the P. knowlesi Duffy-binding protein binds both human
and rhesus Duffy antigens. P. knowlesi b region II binds sialic
acid residues on rhesus erythrocytes, and P. knowlesi g region
II binds as yet unidentified receptors on rhesus erythrocytes
(20, 22). These conserved, receptor binding domains are re-
ferred to as Duffy binding-like (DBL) domains after the binding
domain of P. vivax Duffy-binding protein.
DBL domains are also found in the extracellular region of the
P. falciparum erythrocyte membrane protein-1 (PfEMP-1) fam-
ily of proteins that are expressed on the surface of P. falcipa-
rum-infected trophozoites and schizonts (23–25). Some mem-
bers of the PfEMP-1 family bind endothelial receptors such as
CD36, ICAM-1, vascular cell adhesion molecule, E-selectin,
CD31, chondroitan sulfate A, and hyaluronic acid to mediate
cytoadherence, which is responsible for sequestration of P.
falciparum trophozoites and schizonts in the deep vasculature
of various host organs (26–31). Binding to ICAM-1 is thought to
be important for sequestration in brain capillaries and is im-
plicated in the pathology of cerebral malaria (32). Binding to
hyaluronic acid and chondroitan sulfate A is important for
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sequestration in the placenta, which often leads to complica-
tions in pregnancy (30, 33). DBL domains derived from
PfEMP-1 have been shown to bind ICAM-1, chondroitan sulfate
A, CD31, and uninfected erythrocytes (34–39).
DBL domains are thus used by different Plasmodium species
to bind diverse host receptors to mediate erythrocyte invasion
and cytoadherence, two mechanisms that are central to ma-
laria pathogenesis. It is important to understand the structural
basis of the interaction of DBL domains with host receptors.
This may allow the development of receptor-blocking agents
that inhibit invasion or reverse cytoadherence. Receptor bind-
ing DBL domains are also attractive vaccine candidates be-
cause antibodies directed against such functional domains may
block their interaction with erythrocytes or endothelial
receptors.
Here, we describe methods to produce milligram quantities
of correctly folded recombinant PvRII, the binding domain of P.
vivax Duffy-binding protein, which contains around 350 amino
acids, including 12 cysteines. Recombinant PvRII has been
expressed in Escherichia coli purified from inclusion bodies
under denaturing conditions and refolded in vitro into its na-
tive conformation. We demonstrate that refolded PvRII is
highly immunogenic and elicits high titer antibodies that can
inhibit the binding of P. vivax Duffy-binding protein to eryth-
rocytes, providing support for the development of recombinant
PvRII as a vaccine candidate for P. vivax malaria. Large scale
production of functional DBL domains is now possible, opening
avenues for more extensive biochemical, structural, and immu-
nological studies.
MATERIALS AND METHODS
Plasmid Constructs and E. coli Strains Used for Recombinant Ex-
pression of PvRII—DNA encoding PvRII (amino acids 194–521 of P.
vivax Duffy-binding protein) fused to hexa-histidine (6-His) at the C-
terminal end was amplified by polymerase chain reaction using primers
59-GCA TGC CAT GGA TCA TAA GAA AAC GAT CT-39 and 59-CGA
GTG TCG ACT CAG TGA TGG TGA TGG TGA TGT GTC ACA ACT
TCC TGA GT-39 and a plasmid containing the gene encoding P. vivax
Duffy-binding protein as template (18). The polymerase chain reaction
product was digested with NcoI and SalI and cloned as a NcoI-SalI
fragment downstream of the T7 promoter in expression vector
pET28a1 (Novagen) to yield plasmid pVPET1. E. coli BL21 (DE3)
strain (Novagen) was transformed with plasmid pVPET1 and used for
expression of recombinant PvRII.
Expression of PvRII in E. coli—Luria broth containing kanamycin
(50 mg/ml) was inoculated with E. coli BL21(DE3)pVPET1 and cultured
overnight at 37 °C. Fresh Luria broth containing kanamycin (25 mg/ml)
was inoculated with the overnight culture at a dilution of 1:50 and
cultured at 37 °C to an A600 nm of 0.6–0.8. Expression of PvRII was
induced by adding isopropyl-1-thio-b-galactopyranoside to the culture
at a final concentration of 1 mM. Induced cultures were allowed to grow
for 4 h at 37 °C.
Isolation of Inclusion Bodies and Purification of Recombinant PvRII
by Metal Affinity Chromatography under Denaturing Conditions—AF-
ter induction, E. coli cells were harvested by centrifugation, washed in
chilled wash buffer (10 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 mM
NaCl), resuspended in chilled lysis buffer (10 mM Tris, pH 8.0, 5 mM
benzamidine-HCl, 2 mM phenylmethylsulfonyl fluoride, 10 mM EDTA,
100 mM NaCl, 200 mg/ml lysozyme), and lysed by sonication. Inclusion
bodies were collected by centrifugation of lysed cells at 4 °C, solubilized
in 10 mM Tris buffer, pH 8.0, containing 6 M guanidine hydrochloride
(GdnHCl), and treated with 10 mM dithiothreitol (DTT) for 2 h at 37 °C.
After removal of DTT by ultrafiltration using filters with 10-kDa cutoff,
recombinant PvRII was purified from solubilized inclusion bodies by
metal affinity chromatography under denaturing conditions using a
nickel nitrilotriacetic acid column as described by the manufacturer
(Qiagen). Solubilized inclusion bodies were loaded on a nickel nitrilo-
triacetic acid column previously equilibrated with equilibration buffer
(10 mM Tris, pH 8.0, 100 mM NaH2PO4, 6 M GdnHCl). The column was
washed with equilibration buffer at pH 6.3, and bound protein was
eluted using a pH gradient starting at pH 6.3 and ending at pH 4.3. The
final concentration of the purified protein was adjusted to ;4.5 mg/ml
with equilibration buffer.
Refolding PvRII by Rapid Dilution—Purified PvRII was refolded by
100-fold dilution in refolding buffer containing 50 mM phosphate buffer,
pH 7.2, 1 mM reduced glutathione, 0.1 mM oxidized glutathione, 1 M
urea, and 0.5 M arginine so that the final protein concentration was ;45
mg/ml. Refolding was allowed to proceed at 10 °C for 36 h with stirring.
At the end of 36 h, the refolding solution was dialyzed for 48 h against
dialysis buffer (50 mM phosphate buffer, pH 6.5, 1 M urea) to remove
arginine before proceeding with purification by ion-exchange
chromatography.
Purification of Refolded PvRII by Ion Exchange and Gel Filtration
Chromatography—After removal of arginine by dialysis, the refolded
protein was loaded on an SP-Sepharose column equilibrated with 50
mM phosphate buffer, pH 6.5. The bound protein was eluted with a
linear gradient of NaCl (100 mM NaCl to 1.5 M NaCl). Fractions con-
taining refolded PvRII were pooled, and PvRII was further purified by
gel filtration chromatography using a Superdex 75 column (Amersham
Pharmacia Biotech). For gel filtration chromatography, 50 mM phos-
phate buffer, pH 7.2, containing 200 mM NaCl was used.
Analysis of Refolded, Purified PvRII by Reverse Phase Chromatogra-
phy—Refolded PvRII was loaded on a reverse phase C8 column. The
gradient used for elution was developed using Buffer A (0.05% triflu-
oroacetic acid in water) and Buffer B (0.05% trifluoroacetic acid in 90%
acetonitrile, 10% water). The column was initially equilibrated with
90% Buffer A and 10% Buffer B and reached a composition of 10%
Buffer A and 90% Buffer B in 40 min.
N-terminal Sequencing and Mass Spectral Analysis of Refolded, Re-
combinant PvRII—Automated Edman degradation was carried out us-
ing an Applied Biosystems 491 protein sequencer using standard meth-
ods. Approximately 100 pmol of purified refolded PvRII was used for the
N-terminal sequencing reaction. Mass spectral analysis of refolded,
purified PvRII was performed by electron spray ionization mass spec-
troscopy using a Hewlett Packard HP100 Series LC/MSD mass spec-
trometer by standard procedures.
Detection of Free Thiols in Refolded, Recombinant PvRII—Analysis of
free protein thiol was carried out using 5,59-dithiobis(2-nitrobenzoic
acid) (DTNB) according to the method of Ellman (40). The sensitivity of
the assay was determined using known amounts of cysteine. Free thiol
could be clearly detected at a concentration of 30 mM. The presence of
free thiols in refolded, purified PvRII was determined in the presence of
6 M GdnHCl to promote side chain availability.
Circular Dichroism (CD) Spectra—CD spectra were recorded on a
Jasco-J720 spectropolarimeter. Spectra of purified, refolded PvRII in 10
mM phosphate buffer, pH 7.2, were recorded as the average of 10
individual spectral scans in the far-UV region from 184 to 260 nm using
a cuvette with a path length of 0.1 cm and the following instrument
parameters: instrument sensitivity, 1 millidegrees; response time, 2 s;
scan speed, 50 nm/min. Concentration of PvRII used for CD spectros-
copy was measured by the BCA protein assay method (Pierce) using
bovine serum albumin as a standard. Deconvolution of the CD spectra
was performed using the method of Bohm et al. (41).
Erythrocyte Binding Assay—Blood collected in 10% citrate phosphate
dextrose was stored at 4 °C for up to 4 weeks and washed three times in
RPMI 1640 (Life Technologies, Inc.) before use. Duffy phenotypes of
erythrocytes were determined by standard blood-typing methods using
two antisera (anti-Fya and anti-Fyb) (Ortho-Clinical Diagnostics).
Duffy negative erythrocytes, Fy(a2b2), did not react with either anti-
Fya or anti-Fyb. Duffy-positive erythrocytes used in the erythrocyte
binding assays had the phenotype Fy(a1b1). Refolded PvRII was in-
cubated with Duffy-positive and Duffy-negative human erythrocytes at
room temperature for 1 h to allow binding. The reaction mixture was
layered over dibutylpthalate (Sigma) and centrifuged to collect eryth-
rocytes. Bound protein was eluted from the erythrocytes with 300 mM
NaCl, separated by SDS-PAGE, and detected by Western blot using
rabbit serum raised against a 42-amino acid peptide derived from PvRII
(amino acids 378–420 of P. vivax Duffy-binding protein).
Detection of Inactive PvRII by Immuno-precipitation and Western
Blotting after Preabsorption of Refolded PvRII with Duffy-positive
Erythrocytes—Different quantities of refolded PvRII (100, 200, 400,
800, 2000 ng) were immuno-precipitated as described below using poly-
clonal rabbit serum raised against refolded PvRII, separated by SDS-
PAGE, and detected by Western blotting using a commercially available
mouse monoclonal antibody raised against penta-histidine (5-His) (Qia-
gen) to determine the sensitivity of detection. Immunoprecipitation was
performed by incubating refolded PvRII with a rabbit polyclonal serum
raised against PvRII at a dilution of 1:200 for 1 h on ice and with protein
A-Sepharose beads (Amersham Pharmacia Biotech) at room tempera-
ture for 1 h. The beads were collected by centrifugation and washed
once with 0.5% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 50 mM Tris, pH
Erythrocyte-binding Proteins of Malaria Parasites17112
 by guest, on Septem
ber 13, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
7.4 (NETT) containing 0.5% bovine serum albumin and twice with
NETT buffer without bovine serum albumin. Bound proteins were
eluted by boiling, separated by SDS-PAGE, and detected by Western
blot using a mouse monoclonal antibody directed against 5-His (Qia-
gen). 100 ng of refolded PvRII can be clearly detected by this method.
Refolded PvRII (8 mg) was preabsorbed four times with 800 ml of packed
Duffy-positive human erythrocytes to remove active PvRII before im-
munoprecipitation. Preabsorption with an equal number of Duffy-neg-
ative human erythrocytes was used as a control. Residual PvRII left
after preabsorption was detected by immunoprecipitation and Western
blotting as described.
Animals and Immunization—Rabbits used in this study were pro-
cured from the Animal Facility of the International Center for Genetic
Engineering and Biotechnology, New Delhi, India. Animals were
housed, fed, and used in experiments according to the guidelines set
forth in the National Institutes of Health manual titled Guide for the
Care and Use of Laboratory Animals (National Institutes of Health
Publication 86–23, United States Department of Health and Human
Services, Washington D. C.). Two 8-week-old New Zealand White rab-
bits were immunized with 200 mg of recombinant PvRII emulsified in
complete Freund’s adjuvant and delivered by the subcutaneous route.
The rabbits were boosted on day 28 with 100 mg of PvRII formulated in
incomplete Freund’s adjuvant delivered by the subcutaneous route. One
rabbit was immunized with adjuvant alone according to the schedule
described above to provide control antiserum. Rabbits were bled on days
0 (preimmune), 27, and 42, and the sera were used for immunoassays.
ELISA—Rabbit sera were tested for recognition of recombinant
PvRII using an ELISA. Briefly, wells of flat-bottom Immulon-2 plates
(Dynatech Laboratories) were coated with 0.1 mg of PvRII and blocked
with 5% milk powder solution in phosphate-buffered saline (blocking
buffer). Antigen-coated wells were incubated for 90 min at 37 °C with
100 ml of rabbit serum diluted in blocking buffer. Serial dilutions
(1:2-fold) of sera starting with a 1:1000-fold dilution were tested. After
washing with phosphate-buffered saline and 0.05% Tween 20, 100 ml of
horseradish peroxidase-labeled anti-rabbit IgG antibody (Sigma) di-
luted 1:2000-fold was added to each well and incubated for 60 min at
37 °C. The enzyme reaction was developed with o-phenylenediamine
dihydrochloride as the chromogen and hydrogen peroxide as the sub-
strate. The reaction was terminated by the addition of sulfuric acid, and
the absorbance at 490 nm (A490) was recorded in each well using an
ELISA microplate reader (Molecular Devices). Preimmune sera as well
as adjuvant-alone control sera were used at similar dilutions. To deter-
mine end point titers, the last dilution of test sera yielding an A490 value
1.5 times that obtained with preimmune serum was determined.
Inhibition of Erythrocyte Binding to PvRII Expressed on the Surface
of COS Cells with Antisera Raised against Refolded PvRII—COS7 cells
were cultured as described previously (20). COS7 cells growing in
35-mm-diameter wells at 40–60% confluency were transfected using
Lipofectin with 2.5 mg of plasmid pHVDR22 according to the manufac-
turer’s instructions (Life Technologies, Inc.). Plasmid pHVDR22 was
designed to express PvRII on the surface of mammalian cells (20); it
contains DNA encoding PvRII fused to the signal sequence of Herpes
simplex virus glycoprotein D (HSV gD) at the N terminus and the
transmembrane region and cytoplasmic domain of HSV gD at the C
terminus in a mammalian expression vector (20, 42). The signal se-
quence and transmembrane segment of HSV gD target the fusion
protein to the surface of COS cells. Expression of PvRII on the COS cell
surface was confirmed by immunofluorescence assays, as described
previously using a monoclonal antibody, DL6, directed against HSV gD
sequences in the fusion protein (20, 42). Binding of erythrocytes to
transfected COS cells expressing PvRII on the surface was tested using
an erythrocyte binding assay, as described earlier (20). Briefly, 200 ml of
a 10% suspension of Duffy-positive human erythrocytes was added to 2
ml of media in wells containing transfected COS cells. Erythrocytes
were allowed to settle for 2 h at 37 °C. Non-adherent erythrocytes were
removed by washing COS cells three times with RPMI. Erythrocyte
binding assays were performed in the presence of different dilutions of
rabbit sera raised against refolded PvRII. Preimmune sera and rabbit
sera raised against adjuvant alone were used as controls. The number
of COS cells covered with rosettes of adherent erythrocytes was scored
in 50 fields at a magnification of 40.
RESULTS
Expression, Purification, and Refolding of Recombinant
PvRII—Recombinant PvRII accumulates in inclusion bodies as
a misfolded, insoluble aggregate when expressed in E. coli.
Misfolded PvRII was solubilized in 6 M GdnHCl, purified by
metal affinity chromatography under denaturing conditions,
and refolded by rapid dilution. Oxidized and reduced glutathi-
one were used during refolding to enable disulfide bond forma-
tion. Conditions such as final concentration of the recombinant
protein after dilution, pH, temperature, duration of refolding,
and concentrations of arginine, urea, glutathione, and oxidized
glutathione were optimized to maximize yield of soluble PvRII
after refolding. Refolded PvRII was purified by ion-exchange
chromatography and gel filtration chromatography as
described.
Refolded, purified PvRII was separated by SDS-PAGE and
detected by silver staining (Fig. 1A). Densitometry scanning of
silver-stained gels indicates that the purity of recombinant
PvRII is greater than 98%. Yields of purified, refolded PvRII
are ;2 mg/liter E. coli culture. Recombinant PvRII migrates
with the expected mobility of ;39 kDa.
Biochemical, Biophysical, and Functional Characterization
of Refolded and Purified PvRII—Refolded and purified PvRII
was characterized using a variety of biophysical, biochemical,
and functional assays. N-terminal sequencing of recombinant
PvRII yields the sequence MDHKKTISSAINHA, which is iden-
tical to the expected sequence. No other sequence is detected.
The molecular mass of recombinant PvRII measured by elec-
tron spray ionization mass spectroscopy is 39,803 Da. The
predicted mass of PvRII with a 6-His fusion if all 12 cysteines
are disulfide-linked is 39,802 Da. N-terminal sequencing and
mass spectroscopic data confirm the identity of recombinant
PvRII. The mobility of refolded PvRII by gel filtration chroma-
tography on a Superdex 75 column is consistent with an ap-
parent molecular mass of ;39 kDa, indicating that purified
PvRII does not form aggregates or multimers (data not shown).
Refolded PvRII migrates slower on SDS-PAGE gels after
reduction with DTT, indicating that disulfide linkages are pres-
ent in the refolded protein (Fig. 1B). The homogeneity of re-
folded PvRII was analyzed by reverse phase chromatography, a
method that can be expected to separate different conformers of
the same protein based on differences in surface hydrophobic-
ity. Refolded PvRII elutes as a single symmetric peak by re-
verse phase chromatography on a C-8 column, suggesting that
the final purified product is homogeneous (Fig. 2). Reduction of
refolded PvRII with DTT results in an increase in elution time
by 1 min, confirming the presence of disulfide linkages in the
refolded protein (Fig. 2). Free thiol content in refolded PvRII
was assayed using the method of Ellman (40) to further assess
the oxidation state of the refolded protein. Free thiol could be
clearly detected at a concentration of 30 mM in this assay. No
FIG. 1. Refolded and purified recombinant PvRII. A, silver-
stained SDS-PAGE gel of refolded and purified PvRII. Different quan-
tities (0.6 mg, 1.0 mg, and 2.0 mg) of refolded and purified PvRII were
reduced, denatured, separated by SDS-PAGE, and detected by silver-
staining. B, mobility of refolded and purified PvRII by SDS-PAGE
before and after reduction. Refolded PvRII has slower mobility by
SDS-PAGE after reduction with dithiothreitol (1DTT), indicating the
presence of disulfide linkages. Molecular mass markers in kDa are
shown.
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free thiols were detected in recombinant PvRII at a concentra-
tion of 50 mM. Considering that PvRII contains 12 cysteines,
this indicates that greater than 95% of cysteines are disulfide
linked.
CD spectroscopy was used to probe the secondary structure
of refolded PvRII. The CD spectrum of PvRII shows character-
istic a-helical signature minima at 208 and 222 nm (Fig. 3).
Deconvolution of the CD spectrum by the method of Bohm et al.
(41) indicates the following distribution of secondary structure
components for PvRII: 52.6% a-helices, 9.8% b-sheets, 14.0%
b-turns, and 21.8% random-coils. The sum of secondary struc-
tural elements calculated from the CD spectrum totals 98.2%,
showing confidence in the measurement and deconvolution.
Spectra recorded on three different batches of refolded PvRII
are identical. Denaturation of refolded PvRII with 6 M GdnHCl
results in loss of minima at 208 and 222 nm, indicating disrup-
tion of a-helical structures.
An erythrocyte binding assay was used to test whether re-
folded PvRII is functional. Recombinant PvRII was incubated
with Duffy-positive and Duffy-negative human erythrocytes to
allow binding. Erythrocytes with bound protein were collected
by centrifugation. Bound protein was eluted with 300 mM NaCl,
separated by SDS-PAGE, and detected by Western blot. Rabbit
serum raised against a 42-amino acid peptide derived from
PvRII was used to detect bound PvRII. Refolded PvRII binds
Duffy-positive human erythrocytes but not Duffy-negative hu-
man erythrocytes (Fig. 4A). Refolded PvRII thus binds eryth-
rocytes with the same specificity as P. vivax Duffy-binding
protein, indicating that it is correctly folded in its functional
conformation. Rabbit serum reacts with a high molecular
weight erythrocyte-derived protein that is released due to red
cell lysis upon the addition of NaCl for elution of bound protein.
Preimmune rabbit serum collected before immunization with
PvRII also reacts with this erythrocyte-derived protein (data
not shown).
What fraction of refolded PvRII is functionally active and
correctly folded? Preabsorption of refolded PvRII with erythro-
cytes followed by detection of residual PvRII by immunopre-
cipitation and Western blotting was used to detect incorrectly
folded PvRII. Approximately 100 ng of PvRII is clearly detected
by this method. Duffy-positive and Duffy-negative human
erythrocytes were used to preabsorb 8 mg of refolded PvRII. No
residual PvRII was detected when Duffy positive erythrocytes
were used for preabsorption (Fig. 4B). On the other hand Duffy-
negative erythrocytes failed to absorb PvRII. Considering that
sensitivity of detection of PvRII is 100, and 8 mg of refolded
PvRII was used, the inability to detect residual protein after
preabsorption indicates that at least 98.75% of refolded PvRII
is removed by preabsorption and is functional.
Immunogenicity of Refolded PvRII and Inhibition of Eryth-
rocyte Binding to PvRII with Antisera Raised against Refolded
PvRII—Refolded PvRII formulated in Freund’s adjuvant was
used to immunize rabbits. Titers for reactivity of rabbit sera
with PvRII were determined by ELISA. Sera from two immu-
nized rabbits had titers of 1:64,000 and 1:32,000, indicating
that PvRII is highly immunogenic.
The ability of rabbit sera to block binding of PvRII to eryth-
FIG. 3. CD spectra of refolded and purified PvRII. CD spectra of
recombinant PvRII are shown before (solid line) and after (broken line)
denaturation with 6 M GdnHCl. Minima near 208 and 222 nm and a
maximum near 190 nm indicate the presence of significant a-helical
content in the refolded protein. Denaturation of refolded PvRII with 6 M
GuHCl results in loss of minima at 208 and 222 nm.
FIG. 2. Reverse phase high perform-
ance liquid chromatography profile
of refolded and purified PvRII before
and after reduction. Refolded, purified
PvRII was analyzed by reverse phase
chromatography on a C8 column. The gra-
dient used for elution was developed us-
ing Buffer A (0.05% trifluoroacetic acid in
water) and Buffer B (0.05% trifluoroacetic
acid in 90% acetonitrile, 10% water). The
column was initially equilibrated with
90% Buffer A and 10% Buffer B and
reached a composition of 10% Buffer A
and 90% Buffer B in 40 min. Refolded
PvRII elutes as a single, symmetric peak,
indicating that it contains a single, homo-
geneous population of conformers. Reduc-
tion of refolded PvRII results in a shift in
elution time by 1 min. AU, absorbance
units.
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rocytes was tested in an erythrocyte binding assay. COS cells
were transfected with constructs designed to express PvRII
fused with the signal sequence and transmembrane domain of
HSV gD at the amino and carboxyl ends, respectively, to target
the P. vivax domain to the cell surface (20). Monoclonal anti-
body DL6 directed against HSV gD sequences in the fusion
protein confirmed expression of PvRII on the COS cell surface
(20, 42). Transfection efficiencies were in the range of 15–20%.
Erythrocyte binding assays were performed 48–60 h after
transfection. COS cells were incubated with Duffy-positive hu-
man erythrocytes in the presence of either preimmune serum,
serum from a rabbit immunized with adjuvant alone, or differ-
ent dilutions of serum from a rabbit immunized with PvRII.
The number of COS cells covered with rosettes of erythrocytes
was scored in 50 fields at a magnification of 40. Results of one
of three similar experiments are shown in Table I. Rabbit
serum raised against refolded PvRII completely blocks binding
of erythrocytes to COS cells expressing PvRII up to a dilution of
1:2500. These data indicate that refolded PvRII can be used to
elicit high titer antibodies that are capable of inhibiting bind-
ing of P. vivax Duffy-binding protein to erythrocytes.
DISCUSSION
The functional binding domains of erythrocyte-binding pro-
teins of Plasmodium sp. map to region II, the conserved, N-
terminal, cysteine-rich regions that are also referred to as DBL
domains (20, 21). Functional domains of PfEMP-1 that mediate
rosetting as well as binding to endothelial receptors such as
ICAM-1, chondroitan sulfate A, and CD31 have also been
mapped to DBL domains (34–39). DBL domains thus play
central roles in two important pathogenic mechanisms, namely
erythrocyte invasion and cytoadherence. To dissect the struc-
tural basis for the interaction of DBL domains with host recep-
tors, it is necessary to obtain the three-dimensional structures
of DBL domains and map receptor-binding sites within these
functional domains. We have previously shown that binding
residues map to a central 170-amino acid stretch between the
fourth and seventh cysteines of PvRII (22). Here, we describe
methods to produce milligram amounts of recombinant PvRII
in its functional conformation and present biochemical, bio-
physical, and functional characterization of the recombinant
domain.
Recombinant PvRII was expressed in E. coli, purified from
inclusion bodies under denaturing conditions, refolded in vitro
by the method of rapid dilution, and further purified by ion
exchange chromatography and gel filtration chromatography.
The final product was shown to be pure, homogenous, and
functional. Purified PvRII is greater than 98% pure as deter-
mined by densitometry scanning of silver-stained SDS-PAGE
gels. The mobility of purified PvRII by gel filtration chroma-
tography is consistent with an apparent molecular weight of
;39 kDa, indicating that purified PvRII does not form aggre-
gates or multimers. Moreover, refolded PvRII elutes as a sin-
gle, symmetrical peak by reverse phase chromatography, sug-
gesting that it contains a single, homogeneous population of
conformers. Importantly, refolded PvRII binds Duffy-positive
human erythrocytes but not Duffy-negative human erythro-
cytes, indicating that it is folded in its functional conformation.
No residual PvRII is detected after preabsorption of refolded
PvRII with Duffy-positive human erythrocytes. Considering
that the detection limit for PvRII is 100 ng, and 8 mg of refolded
PvRII was used, the inability to detect residual PvRII after
preabsorption with Duffy-positive human erythrocytes indi-
cates that greater than 98.75% of refolded PvRII is functional.
The CD spectrum of refolded PvRII indicates the presence of
significant a-helical content, as has been predicted for DBL
domains (43). It remains to be experimentally determined if
other DBL domains also contain high a-helical content. Impor-
tantly, CD spectra recorded for different batches of refolded
PvRII are identical, implying conformational consistency in the
refolded product produced by the method described.
The binding domain of P. vivax Duffy-binding protein, PvRII,
is a promising vaccine candidate since antibodies directed
against this functional domain may block erythrocyte binding
and invasion by P. vivax. Rabbit sera raised against refolded
PvRII recognize PvRII up to dilution of 1:64,000 by ELISA,
indicating that refolded PvRII is highly immunogenic. Sera
from immunized rabbits completely inhibit erythrocyte binding
to COS cells expressing PvRII on the surface up to a dilution of
1:2500. These data indicate that recombinant PvRII can elicit
FIG. 4. Erythrocyte binding assay with refolded and purified
PvRII. A, erythrocyte binding assay. Refolded PvRII was incubated
with Duffy-positive (Fy(a1b1)) and Duffy-negative (Fy(a2b2)) eryth-
rocytes to allow binding. Erythrocytes and bound protein were collected
by centrifugation. Bound PvRII was eluted with 300 mM NaCl, sepa-
rated by SDS-PAGE, and detected by Western blotting using a rabbit
antiserum raised against a 42-amino acid peptide derived from PvRII.
Refolded PvRII specifically binds Duffy-positive (Fy(a1b1)) but not
Duffy-negative ((Fy(a2b2)) human erythrocytes. B, detection of inac-
tive PvRII by immunoprecipitation and Western blotting after preab-
sorption with Duffy-positive erythrocytes. Residual PvRII was immu-
noprecipitated, separated by SDS-PAGE, and detected by Western blot
either after preabsorption with Duffy-positive (Fy(a1b1)) or Duffy-
negative (Fy(a2b2)) human erythrocytes or without preabsorption (2).
MW, Mr.
TABLE I
Inhibition of erythrocyte binding to PvRII expressed on the surface of
COS cells with rabbit serum raised against refolded, purified PvRII
Antisera Dilution No. of rosettes in50 fieldsa
None NA 1111
Preimmune 1:10 1111
Adjuvant control 1:10 111
Anti-PvRII 1:250 2
Anti-PvRII 1:500 2
Anti-PvRII 1:1,000 2
Anti-PvRII 1:2,500 2
Anti-PvRII 1:5,000 1
Anti-PvRII 1:7,500 11
Anti-PvRII 1:10,000 111
a Numbers of COS cells covered with rosettes of red blood cells were
scored in 50 fields at a magnification of 40. The average number of
rosettes found in two wells is reported. 1, 25–50 rosettes; 2, no rosettes
seen. NA, not applicable. Results from one of three similar experiments
are reported.
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high titer binding inhibitory antibodies, providing support for
the development of recombinant PvRII as a vaccine for P. vivax
malaria. Due to the difficulty in culturing P. vivax, it is not
possible to test antibodies raised against PvRII for inhibition of
erythrocyte invasion by P. vivax. Antibodies raised against the
binding domain of P. falciparum EBA-175 have been shown to
inhibit erythrocyte invasion by P. falciparum in vitro (44).2 By
analogy, antibodies directed against PvRII can be expected to
effectively block erythrocyte invasion by P. vivax.
Individuals living in endemic areas develop binding inhibi-
tory antibodies directed against PvRII after repeated exposure
to P. vivax infection (45). However, naturally acquired binding
inhibitory antibodies are of low titer. Moreover, human sera
from individuals residing in endemic areas completely block
binding of erythrocytes to COS cells expressing PvRII only up
to a dilution of 1:10 (45). Here, we have shown that rabbit sera
raised against refolded PvRII inhibit erythrocyte binding to
COS cells expressing PvRII up to a dilution of 1:2500. It re-
mains to be determined if the presence of high titer antibodies
that inhibit binding of P. vivax Duffy-binding protein to eryth-
rocytes will confer protection against P. vivax malaria.
Recombinant PvRII has been previously expressed in its
functional form as a secreted protein in insect cells using bacu-
loviral vectors (46). Recombinant proteins expressed as se-
creted proteins in eukaryotic cells are commonly glycosylated,
which is often a disadvantage for crystallographic studies. Pre-
vious attempts to express PvRII in its functional form using
bacterial expression systems have been unsuccessful (11, 46).
This report is the first description of methods developed for
refolding and purification of functional PvRII produced in a
bacterial expression system. These methods should be applica-
ble to DBL domains derived from other erythrocyte-binding
proteins and from extracellular regions of PfEMP-1. Indeed, we
have used similar methods to express, purify, and refold P.
falciparum region F2, the binding domain of P. falciparum
EBA-175. Refolded P. falciparum region F2 specifically binds
sialic acid residues of human glycophorin A.2 The availability of
methods for large scale production of correctly folded DBL
domains is an important step for structural studies as well as
for malaria vaccine development efforts based on these func-
tional receptor binding domains.
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